The global bronchitis treatment market is anticipated to witness growth over the forecast period. The major factor that propels the market growth includes a large patient pool.
Bronchitis is a respiratory disease in which there is inflammation of the bronchi in the lungs. In other words, bronchitis is an inflammation of the lining of bronchial tubes that carry air to and from the lungs. Some of the common signs and symptoms of bronchitis include cough, fatigue, shortness of breath, chest discomfort, production of mucus, etc.
The risk factors that increase the chances of bronchitis include cigarette smoking, gastric reflux, exposure to irritants during work such as chemicals, fumes, dust, etc., pollution, allergies, malnutrition, passive smoking, and so on. One of the most common complications of bronchitis is pneumonia that usually occurs when the infection spreads deeper into the lungs. This infection thereby causes the air sacs in the lungs to fill with fluid.
Bronchitis is classified into two type’s namely acute bronchitis and chronic bronchitis. Acute bronchitis is a short term inflammation of the bronchi of the lungs. Acute bronchitis is also known as a chest cold. Maximum cases of acute bronchitis are caused by viruses. The most common symptom of acute bronchitis is cough. The other symptoms include fever, shortness of breath, wheezing, etc.
Chronic bronchitis is a serious and long-term inflammation of the bronchi of the lungs. It is one of the several lung diseases that are collectively known as chronic obstructive pulmonary diseases. Chronic bronchitis is usually caused by repeated irritation and damage to the lung and airway tissue.
The major factor that propels the growth of the global Bronchitis Treatment Market includes a large patient pool. In addition, the other essential factors that drive the growth of the market include unhealthy habits such as smoking, and also the rising level of chemical pollutants. Moreover, sedentary lifestyle and availability of treatment for bronchitis are also fueling the growth of the Bronchitis Treatment Market.
On the other hand, there are also factors that hamper the growth of the market such as patent expiry. The global Bronchitis Treatment Market is classified on the basis of treatment, class of drugs, end user, and geography. On the basis of treatment, the global market is classified as drugs and oxygen therapy. On the basis of the class of drugs, the global market is classified as antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. On the basis of end user, the global market is classified as hospitals, clinics, and drug stores. On the basis of geography, the global market is classified as North America, Latin America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan, and Middle East & Africa.
The North American region comprises the U.S. and Canada. Latin America comprises Mexico and Brazil. The Western European region comprises Germany, Italy, France, England, Spain, Nordic countries, Belgium, Netherlands, and Luxembourg. The Eastern European region comprises Poland and Russia. Asia Pacific region comprises China, India, ASEAN, and Australia & New Zealand. The Middle East and Africa region comprise GCC, South Africa, and North Africa.
In the case of geographical region, North America accounts for a major share of the global market owing awareness regarding health among people and also well-established healthcare infrastructure and facilities.
The North American region is followed by Europe. Europe presents the second position in the global Bronchitis Treatment Market. Whereas, Asia Pacific is projected to witness the fastest growth and shows significant market share over the forecast period. Some of the prominent players that fuel the growth of the global market include Boehringer Ingelheim, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline Pharmaceuticals Limited, Pfizer Inc., Sanofi Aventis, etc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.